Therapeutic | Lokivetmab |
Target | IL31 |
Heavy Chain | EVQLVESGGDLVKPGGSLRLSCVASGFTFSNYGMSWVRQAPGKGLQWVATISYGGSYTYYPDNIKGRFTISRDNAKNTLYLQMNSLRAEDTAMYYCVRGYGYDTMDYWGQGTLVTVSS |
Light Chain | EIVMTQSPASLSLSQEEKVTITCKASQSVSFAGTGLMHWYQQKPGQAPKLLIYRASNLEAGVPSRFSGSGSGTDFSFTISSLEPEDVAVYYCQQSREYPWTFGQGTKLEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Canine Whole mAb |
Isotype | G2 |
Highest Clinical Trial (June '19) | Approved |
Estimated Status (June '19) | NFD |
Recorded Developmental Technology | na |
INN Year Proposed | 2014 |
INN Year Recommended | 2015 |
Companies Involved | Zoetis |
Conditions Approved | Canine atopic dermatitis |
Conditions Active | na |
Conditions Discontinued | na |
Notes |